Pathological features, clinical presentations and prognostic factors of ovarian large cell neuroendocrine carcinoma: a case report and review of published literature
Authors:
Open Access
- 25 July 2019
- journal article
- review article
- Published by Springer Nature in Journal of Ovarian Research
- Vol. 12 (1) , 1-11
Abstract
There is no consensus on the optimal chemotherapy regimen and the prognostic factors for ovarian large cell neuroendocrine carcinoma (LCNEC), a rare type of tumor. The objective of the present study is to present the case of a recent encounter of pure ovarian LCNEC and perform a brief review to summarize the clinicopathological features and prognostic factors of 57 cases of LCNEC patients that have been previously reported. Eligible studies were searched for online and 57 cases with clear follow-up data were found to have been reported. We present the 58th case, which is of a 70-year-old woman with stage IIIc primary pure LCNEC of the ovary. The initial symptom of this patient was abdominal distension (more than 2 months). A recent ultrasound test showed a solid-cystic mass occupying the pelvic and abdominal cavity. She received two courses of cisplatin-etoposide chemotherapy as an adjuvant therapy. No signs of nonclinical or radiological evidence of disease recurrence was found at follow-up examinations during the first 3 months after operation. A retrospective review of these 58 cases was conducted and survival curves were estimated. Using the Kaplan-Meier method. The patients included were aged between 18 and 80 years. A Kaplan-Meier survival curve revealed that the median overall survival was 10.000 months, while 26 (44.83%) patients died within 12 months. We compared the overall mean survival time of all patients with that of stage I patients (42.418 vs 42.047 months), which suggests that ovarian LCNEC has a very poor prognosis even at stage I. Mean survival was longer for patients who had undergone postoperative chemotherapy than for those without postoperative chemotherapy (48.082 vs 9.778 months). A small series, such as this, does not provide adequate data to establish a firm correlation between the postoperative chemotherapy and prognosis (p = 0.176). In our review of 58 cases with ovarian LCNEC, prognosis was unfavorable in most cases. Given the rarity of LCNEC, it is highly recommended that a global medical database of ovarian LCNEC and a standard system of diagnosis and treatment is established.Keywords
This publication has 67 references indexed in Scilit:
- Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancerEuropean Journal of Cancer, 2013
- Pure Large Cell Neuroendocrine Carcinoma of Ovary: A Rare Clinical Entity and Review of LiteratureCase Reports in Oncological Medicine, 2012
- Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective seriesAnnals of Oncology, 2012
- Clinical features of ovarian large-cell neuroendocrine carcinoma: Four case reports and review of the literatureExperimental and Therapeutic Medicine, 2011
- Neuroendocrine tumour of the ovaryJournal of Obstetrics and Gynaecology, 2009
- Ovarian large cell neuroendocrine carcinomaJournal of Obstetrics and Gynaecology Research, 2008
- Ovarian neuroendocrine carcinoma, non-small cell type, associated with serous carcinomaGynecologic Oncology, 2007
- Large cell neuroendocrine carcinoma of the ovaryAPMIS, 2007
- Ovarian carcinomas with neuroendocrine differentiation: Review of five cases referring to immunohistochemical characterizationJournal of Obstetrics and Gynaecology Research, 2006
- World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital OrgansHistopathology, 2005